ABSTRACT Background. Patients with relapsed and refractory solid tumors have a poor prognosis. Recent advances in genomic technology have made it feasible to screen tumors for actionable mutations, with the anticipation that this may provide benefit to patients. Methods. Pediatric oncologists were emailed an anonymous 34-question survey assessing their willingness to offer a rebiopsy to patients with relapsed disease for the purpose of tumor genomic profiling. They were presented with two scenarios evaluating morbidity and invasiveness of the procedures using the clinical examples of medulloblastoma and Ewing sarcoma. Results. A total of 195 pediatric oncologists responded to the questionnaire. Morbidity and invasiveness of the procedure demonstrated significant differences in provider willingness to refer their patients for rebiopsy. The pretest probability was a major variable influencing provider willingness to offer a rebiopsy. Respondents were more likely to offer a rebiopsy if the likelihood was high that the results would have an impact on clinical management than if the biopsy was for histologic confirmation alone (mean 89 vs. 56 %; p = 0.017). Compared with the rate of a rebiopsy for histologic confirmation, significantly fewer providers were willing to offer a rebiopsy if they were led to believe the likelihood of finding an actionable mutation was low (mean 45 vs. 56 %; p = 0.021). Conclusion. The scenario showed that the pretest probability of finding an actionable mutation was influential in determining provider willingness to offer a rebiopsy for the purpose of tumor genomic profiling. Further research is warranted to evaluate the benefit of tumor genomic profiling in terms of patient outcomes.
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In contrast to the steep decline in mortality rates for childhood leukemia and lymphoma seen during the past several decades, the decline in the mortality rates for pediatric solid tumors has been modest, and patients with relapsed and refractory solid tumors have a very poor prognosis. 1, 2 Particularly poor outcomes have been highlighted in recent pediatric phase 2 trials for patients who have relapsed solid tumors, with 1-year progression-free survival rates lower than 20 %. [3] [4] [5] Given these poor outcomes and concern that conventional treatments may provide minimal benefit, novel approaches are needed to improve cure rates.
Recent advances in genomic technology have provided platforms that feasibly screen tumors for actionable mutations or alterations in genes that can be targeted with novel drug therapy, with anticipation that knowledge concerning the molecular drivers of the disease may provide benefit to patients. 6 An analysis of patients referred for tumor molecular profiling at MD Anderson showed that patients treated with matched therapy, compared with those enrolled in clinical trials with nonmatched therapy, had a higher rate of objective response (12 vs. 5 %), prolonged median progression-free survival (3.9 vs. 2.2 months), and prolonged median overall survival (11.4 vs. 8.6 months). 7 The assessment of tumors for actionable mutations requires adequate tissue for the analysis. This requires the child to undergo a biopsy, which may be an invasive procedure with a risk of morbidity. Original tumor specimens are not always accessible; nor are they necessarily representative of the biology of the relapsed disease.
No established practice guidelines exist for performing a biopsy of tumors in patients who have relapsed. There is precedent in pediatrics for requiring a biopsy and submission of a specimen for biology companion studies for participation in clinical trials. However, in tumor profiling, although the biopsy is necessary for participation, it offers no guarantee that the analysis will guide the treatment plan. 8, 9 The benefits of tumor profiling must be weighed by the probability of finding an actionable mutation versus the risk of the procedure. 10 This ethical dilemma is faced by practitioners on a daily basis due to the readily available commercial tumor profiling tests. Many of the commercially available tests are marketed directly to consumers. An Internet content analysis study identified 32 websites marketing somatic tumor analysis directly to consumers for the purpose of personalized cancer care.
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This survey evaluated the views of pediatric oncologists on the role of performing a biopsy of relapsed tumors for the purpose of tumor genomic profiling and assessed the variables that have an impact on providers' decisions in referring their patients for a rebiopsy of the relapsed disease.
METHODS

Subjects
The email addresses of 812 practicing pediatric oncologists were obtained via hospital websites and published manuscripts. The pediatric oncologists were emailed a link to an anonymous survey on www.surveymonkey.com. They were sent two subsequent reminder emails to maximize the response rate. The research protocol and survey were approved by the Institutional Review Board (IRB) at the Albert Einstein College of Medicine.
Survey Instrument
The instrument consisted of an Internet-based survey comprising 34 questions involving clinical scenarios designed to address the following domains: physician willingness to perform a biopsy of relapsed tumors, invasiveness, morbidity, and ethical beliefs. The scenarios involved children with relapsed or refractory medulloblastoma or Ewing sarcoma and included questions to evaluate the effect of variations in the likelihood of benefit, invasiveness, and morbidity of the surgical procedures and the willingness of providers to offer a rebiopsy for the purpose of genomic profiling ( Supplementary Fig. 1) . A previously validated survey tool also was included to evaluate provider self-reported confidence and knowledge within specific areas of genomic profiling. 12 To establish face validity, the survey items were vetted with experts in pediatric oncology, clinical genomics, medical ethics, and survey methods.
Statistical Analysis
Descriptive statistics including means, medians, standard deviations, and ranges were computed for continuous variables and frequencies for categorical variables. In addition, bivariate associations between provider demographic characteristics and provider views on genomic profiling of relapsed solid tumors were evaluated by means of a t test for continuous variables and a v 2 test for categorical variables.
RESULTS
Demographics
The survey was sent to 812 pediatric oncologists, 195 of whom responded, with 159 of these responders completing the entire survey, for an overall response rate of 24 % and a survey completion rate of 20 %. The demographic characteristics of the respondents are described in Table 1 . The respondents varied in their current usage of tumor genomic profiling, with 30 % reporting referral of more than five patients, 49 % reporting referral of one-five patients, and 21 % reporting no referral of any patients in the past year (Fig. 1) . The providers were more likely to have referred more than five patients in the past year for tumor genomic profiling if they spent more than 20 % of their time performing basic science research (47 vs. 17 %; p \ 0.0001; Supplementary Fig. 2 ), if they worked in divisions with more than 100 oncology patients per year with a new diagnosis (43 vs. 12 %; p \ 0.0001), and if they had greater confidence in their ability to interpret the results of genomic profiling (35 vs. 17 %; p = 0.03).
Willingness to Perform a Rebiopsy
The respondents' willingness to offer a rebiopsy for the purpose of histologic confirmation was negatively correlated with the degree of morbidity and invasiveness presented in the scenario. In the scenario of medulloblastoma, 30 % of respondents were willing to offer a rebiopsy for histologic confirmation when the morbidity was high, compared with 61 % when the morbidity was low (p \ 0.0001). Fewer respondents were likely to offer a more invasive open procedure for histologic confirmation of relapsed Ewing sarcoma compared with those who would offer a needle or core biopsy for the same purpose (59 vs. 74 %; p = 0.0032).
The likelihood of finding an actionable mutation was a major variable influencing provider willingness to offer a rebiopsy for the purpose of genomic profiling. The respondents were more likely to offer a rebiopsy if they were told the likelihood was high that the results would have an impact on clinical management than if told it was for histologic confirmation alone (mean 89 vs. 56 %; p = 0.017; Fig. 2 ). In contrast, significantly fewer providers were willing to offer a rebiopsy if they were told the likelihood of finding an actionable mutation was low than if told it was for the purpose of histologic confirmation alone (mean 45 vs. 56 %; p = 0.021).
More providers were willing to offer a highly morbid procedure if they were told the likelihood of finding an actionable mutation was high compared with a procedure involving low morbidity that had a low likelihood of finding an actionable mutation (77 vs. 47 %; p \ 0.0001). Similarly, more providers would offer an invasive procedure in the Ewing sarcoma scenario if they believed the likelihood was high that the results would have an impact on clinical management compared with a less invasive procedure that had a low likelihood of finding a result (91 vs. 64 %; p \ 0.0001).
Ethics
More respondents thought it was ethical to offer a rebiopsy if the procedure was associated with a low rate of morbidity versus a high rate of morbidity (78 vs. 47 %; p \ 0.0001; Fig. 3a) . Likewise, fewer respondents found it ethical to offer an open biopsy versus a less invasive procedure for the purpose of genomic profiling (72 vs. 83 %; p = 0.039). Of the 47 % of providers who believed it was ethical to offer a rebiopsy in the scenario with high morbidity, 89 % would offer a rebiopsy if the likelihood of finding an actionable mutation was high. Of the providers who deemed a rebiopsy of a medulloblastoma with 50 % morbidity to be unethical or unsure, 65 % were willing to offer a rebiopsy when told the likelihood of finding an actionable mutation was high (Fig. 3b) . In the high-and low-morbidity medulloblastoma scenarios as well as in the more invasive Ewing sarcoma scenario, if the respondents thought the procedure to be unethical or were uncertain, they were more likely to offer a rebiopsy if led to believe the likelihood of finding an actionable mutation was high than if they considered the procedure ethical but were led to believe the likelihood of finding an actionable mutation was low (p = 0.008, \0.0001, 0.007, respectively).
Genomic Confidence
Providers overall expressed confidence in their ability to incorporate tumor genomic profiling in their practice in the following domains: identifying consultants with expertise in integrating genomic information into patient care (87 %), explaining genomic concepts to patients (80 %), providing psychosocial support to patients coping with adverse prognostic implications from genomic results (78 %), interpreting genomic results within their specific specialty (72 %), and making treatment recommendations based on genomic information (62 %) ( Supplementary  Fig. 3A ). Provider confidence in interpreting genomic results was not associated with a statistically significant change in physicians' decision to offer their patients rebiopsy.
Pediatric oncologists who spent more than 20 % of their time performing basic science or translation research were more confident in their ability to explain genomic concepts to patients (91 vs. 72 %; p = 0.002), to interpret genomic results within their specialty (87 vs. 62 %; p = 0.03), and to make treatment recommendations based on genomic information (76 vs. 53 %; p = 0.006) compared with those who spent less time in research (Supplementary Fig. 3B ). The number of years of experience and the number of patients with a new diagnosis treated annually were not significantly associated with the providers' confidence in interpreting genomic data in any of the parameters. Men were more confident than women in their abilities to explain genomic concepts to patients (86 vs. 72 %; p = 0.04) and to provide psychosocial support (87 vs. 66 %; p = 0.003) (Supplementary Fig. 3C ).
Perception of Benefit
More than half of the providers believed that 20 % or less of patients will benefit directly from tumor genomic profiling ( Supplementary Fig. 4A ). In all scenarios, regardless of the perceived benefit to patients, the providers were more likely to offer a rebiopsy if the likelihood of finding an actionable mutation was high (p \ 0.0001 for all scenarios) (Supplementary Fig. 4B ). Providers who completed their fellowship less than 10 years previously were more likely to feel that more than 20 % of their patients were likely to benefit from tumor genomic profiling (53 vs. 35 %; p = 0.035).
The respondents were divided regarding the appropriateness of performing genomic profiling of relapsed tumors outside the context of an IRB-approved study, with 38 % agreeing, 43 % disagreeing, and 19 % unsure of its importance (Fig. 4b) . The majority of the providers agreed that it is imperative that the genomic profiling be performed in a Clinical Laboratory Improvement Amendments-approved laboratory. 
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DISCUSSION
In surveying pediatric oncology views about the role of rebiopsy aimed at genomic profiling of relapsed disease, this study found that the scenario-defined likelihood of finding an actionable mutation was highly influential in the providers' decision to offer rebiopsy. The degree of morbidity and invasiveness associated with the procedure, as well as the ethical beliefs of the provider, also influenced the providers' willingness to offer rebiopsy to their patients.
The majority of the respondents in this survey indicated their willingness to offer their patients a rebiopsy if told the probability of finding an actionable mutation is high. Yet, more than half of the respondents believed that less than 20 % of their patients would benefit from tumor genomic profiling. This discrepancy might be explained by understanding that the probability of finding an actionable mutation may vary by diagnosis. When told that the patient has a high likelihood of an actionable mutation being found, there is the supposition that this patient has features placing him or her in the subset likely to derive benefit. Another possible explanation for this disparity may be the respondents' concerns regarding access to therapeutic agents targeting the actionable mutations, especially in the pediatric population, or it may be that the agents currently available do not necessarily generate a response in their patients even if they have an actionable mutation. At baseline, we found that providers who devoted more than 20 % of their time conducting basic science research were significantly more likely to have referred more than five patients for tumor genomic profiling. A significantly greater number of these individuals also were likely to report confidence in their abilities to ''explain genomic concept to patients,'' to ''interpret genomic results,'' and to ''make treatment recommendations based on genomic information.'' This implies that providers' confidence in their ability to interpret the results of genomic profiling may play a role in the number of patients they refer to genomic testing. Given the number of respondents, a multivariate analysis could not be performed to validate this relationship. However, it does suggest a possible role of education or streamlining the reporting of the results to improve the understanding of the providers.
In this survey, men were more likely than women to report confidence in their ability to explain genomic concepts to patients and to provide psychosocial support. This may be explained in part by the fact that men comprised a much larger proportion (72 %) of the individuals who spent more than 20 % of their time conducting basic science research (data not shown). However, other factors may exist beyond the scope of this instrument that explain this finding. Whereas men were significantly more likely to report confidence in providing psychosocial support, respondents who spent more than 20 % of their time conducting basic science research were less likely to report confidence in that domain, but this difference did not reach the level of statistical significance.
This study examined the possible forces influencing the decision of pediatric oncologists to refer their patients for biopsy for the purpose of tumor genomic profiling. Prior studies have examined the ethical considerations of tissue collection for research purposes. [8] [9] [10] 13 Children, as protected subjects, pose an even greater ethical concern because any additional procedure above minimal risk for the purpose of research merits greater scrutiny.
However, in the case of biopsy for tumor genomic profiling, the purpose of the biopsy is not only for research but also for the direct benefit of the patient. This is complicated further by the expectation that an actionable mutation will be found in only a subset of patients. Furthermore, although the results for some diseases such as lung cancer have been encouraging in terms of targeted therapy for patients with EGFR or ALK mutations, data for the outcomes of tumor genomic profiling in pediatric cancer have been limited.
Recently, a survey of medical oncologists at the Dana Farber Cancer Institute and the Brigham and Women's Hospital examined physicians' attitudes about tumor genomic profiling. Similar to their pediatric oncology counterparts in this survey, the majority of medical oncologists were confident in their ability to interpret the results of tumor genomic profiling. Also similarly, the physicians varied in their belief concerning the percentage of patients for which this testing would be applicable. 12 This may reflect the yet undefined role and benefit of this evolving technology. The perception of direct benefit from genomic profiling of relapsed/refractory solid tumors by the pediatric oncologists surveyed is in line with preliminary results of tumor profiling studies in this patient population. 14, 15 This suggests a relatively high level of proficiency with genomic data in the pediatric oncology community. However, providers who completed their fellowship less than 10 years ago were more likely to believe that more than 20 % of their patients would benefit from tumor genomic profiling. This may be showing a gap in the education of trainees about the potential value and limitations of this powerful technology for their patients.
This study had several potential limitations. The sample was small, partly due to the limited number of pediatric oncologists and the response rate, which may have imparted a degree of nonresponse bias. Another limitation was the scope of the instrument used in the survey. The data reflect the participants' responses to hypothetical situations and may not accurately reflect their practice patterns. Furthermore, the study was cross-sectional, analyzing bivariate relationships, so no causal inferences can be made, but this work can inform future inquiries in this area of research.
Tumor genomic profiling plays an increasing role in the care of pediatric oncology patients. The President's announcement of the Precision Medicine Initiative heralds the arrival of a new era in cancer research, with molecular diagnostics playing an integral role in diagnosis, prognosis, and treatment. 16 This study provides an early step toward understanding providers' perceptions and potential barriers to rebiopsy for the purpose of acquiring this new variety of clinical data.
Further research is necessary to evaluate the practice patterns of oncologists with respect to the use of this evolving technology. Likewise, further research is warranted to evaluate the benefit of tumor genomic profiling in terms of patient outcomes, with the understanding that such studies will be complicated by issues with design.
